These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 29936620)
1. Switching from CLSI to EUCAST XL susceptibility breakpoint: its implication in urinary tract infection in men. Aguirre-Quiñonero A; Lecaroz Agara MC; Canut Blasco A Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1813-1815. PubMed ID: 29936620 [No Abstract] [Full Text] [Related]
2. Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae. Bunnell KL; Wenzler E; Harrington AT; Danziger LH Diagn Microbiol Infect Dis; 2018 Apr; 90(4):335-336. PubMed ID: 29395714 [TBL] [Abstract][Full Text] [Related]
3. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae. Delgado-Valverde M; Valiente-Mendez A; Torres E; Almirante B; Gómez-Zorrilla S; Borrell N; Aller-García AI; Gurgui M; Almela M; Sanz M; Bou G; Martínez-Martínez L; Cantón R; Antonio Lepe J; Causse M; Gutiérrez-Gutiérrez B; Pascual Á; Rodríguez-Baño J; J Antimicrob Chemother; 2017 May; 72(5):1478-1487. PubMed ID: 28093484 [TBL] [Abstract][Full Text] [Related]
5. Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria. Guibert J; Destrée D; Konopka C; Acar J Eur J Clin Microbiol; 1986 Apr; 5(2):247-8. PubMed ID: 2941292 [No Abstract] [Full Text] [Related]
6. Fluoroquinolones for urinary tract infection and within-household spread of resistant Enterobacteriaceae: the smoking gun. Trautner BW Clin Microbiol Infect; 2018 Sep; 24(9):929-930. PubMed ID: 29649605 [No Abstract] [Full Text] [Related]
7. [Urinary infections by enterobacteriaceae resistent to antimicrobial agents]. Ales Reinlein JM; Vela Navarrete R; Fernández Puentes MC; Silva M Rev Clin Esp; 1973 Aug; 130(4):295-300. PubMed ID: 4755593 [No Abstract] [Full Text] [Related]
8. A case of Raoultella ornithinolytica urinary tract infection in a pediatric patient. Büyükcam A; Liste Ü; Bıçakçıgil A; Kara A; Sancak B J Infect Chemother; 2019 Jun; 25(6):467-469. PubMed ID: 30683499 [TBL] [Abstract][Full Text] [Related]
9. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates. Hombach M; Mouttet B; Bloemberg GV J Antimicrob Chemother; 2013 Sep; 68(9):2092-8. PubMed ID: 23633681 [TBL] [Abstract][Full Text] [Related]
10. Cephalothin susceptibility testing as class representative for oral cephalosporins: is it time to move on? Nguyen HM; Graber CJ Diagn Microbiol Infect Dis; 2013 Aug; 76(4):483-5. PubMed ID: 23680238 [TBL] [Abstract][Full Text] [Related]
11. [Aminoglycoside resistance of enterobacteria isolated from urinary infections in surgical departments]. Muntean D; Licker M; Berceanu-Văduva D; Crăciunescu M; Hogea E; Popa M; Adămut M; Rădulescu M; Moldovan R Bacteriol Virusol Parazitol Epidemiol; 2008; 53(2):99-102. PubMed ID: 19856848 [TBL] [Abstract][Full Text] [Related]
12. Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs. Heil EL; Johnson JK J Clin Microbiol; 2016 Apr; 54(4):840-4. PubMed ID: 26791363 [TBL] [Abstract][Full Text] [Related]
13. CLSI - EUCAST: Comparison of antibiotic-susceptibility profile of Palmeira JD; Ferreira H Acta Microbiol Immunol Hung; 2019 Dec; 66(4):413-422. PubMed ID: 31658837 [TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). Pfaller MA; Bassetti M; Duncan LR; Castanheira M J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526 [TBL] [Abstract][Full Text] [Related]
15. [Antimicrobial susceptibility in urinary tract infections caused by ESBL- and non-ESBL-producing Enterobacteriaceae in hospitalized/outpatient-, sex-, age-matched patients]. Jaqueti-Aroca J; Molina-Esteban L; Limón-Yelmo A; García-Arata I Rev Esp Quimioter; 2018 Feb; 31(1):63-65. PubMed ID: 29390602 [No Abstract] [Full Text] [Related]
16. Empirical treatment of urinary tract infections: how rational are our guidelines? O'Grady MC; Barry L; Corcoran GD; Hooton C; Sleator RD; Lucey B J Antimicrob Chemother; 2019 Jan; 74(1):214-217. PubMed ID: 30295780 [TBL] [Abstract][Full Text] [Related]
17. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143 [TBL] [Abstract][Full Text] [Related]
18. Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa. Van TT; Minejima E; Chiu CA; Butler-Wu SM J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31043468 [TBL] [Abstract][Full Text] [Related]
19. Plasmid-mediated quinolone resistance genes in Enterobacteriaceae isolates associated with community and nosocomial urinary tract infection in East London, UK. Amin AK; Wareham DW Int J Antimicrob Agents; 2009 Nov; 34(5):490-1. PubMed ID: 19261447 [No Abstract] [Full Text] [Related]
20. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints. Kahlmeter G Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():169-74. PubMed ID: 18154542 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]